Parabilis Medicines, Inc.

The stock is still in a post-IPO digestion phase, trading above its 200-day average and closer to the middle of its 52-week range than to either extreme. That keeps the longer-term trend constructive, but the setup still needs sustained follow-through to challenge the prior high near 34.47.

Wall Street tone is positive, with two fresh initiations both landing on the bullish side: Guggenheim at Buy and Evercore ISI at Outperform. The published target cluster is tight at 40, which sits well above the recent trading range and signals room for rerating if clinical progress stays on track.

No earnings history is available yet, so the next report is more about pipeline execution than a beat/miss pattern. Estimates point to a slightly deeper loss next year, with EPS seen at -1.9 versus -1.78 TTM, so shareholders should watch cash use and clinical milestones closely.

No notable insider buying or selling in recent quarters. With no reported transactions, the tape offers no signal on management conviction beyond the company’s public clinical and financing posture.

The business remains loss-making, with EPS at -1.78 TTM and no reported profitability margins yet. Cash burn is heavy: operating cash flow was -123.7 million in 2025, while cash and equivalents stood at 27.7 million, so funding runway and trial spend matter.

As a clinical-stage biotech, PBLS is valued on pipeline optionality rather than current earnings power. The market is pricing in a premium path, with the share price still below the 40 consensus target and well above the low end of its 52-week range.